Complement Therapeutics Doses First Patient in Opti-GAIN Study for AMD-Related Vision Loss Complement Therapeutics has initiated its groundbreaking Phase I/II Opti-GAIN study, with the first patient dosed with CTx001 for Geographic Atrophy related to AMD.

Complement Therapeutics Doses First Patient in Opti-GAIN Study for AMD-Related Vision Loss #Germany #Munich #Geographic_Atrophy #Complement_Therapeutics #CTx001

First European Patient Enrolled in ONL Therapeutics' Phase 2 GALAXY Trial for Geographic Atrophy ONL Therapeutics marks a significant milestone with the enrollment of its first European patient in the Phase 2 GALAXY trial for treating geographic atrophy linked to dry AMD.

First European Patient Enrolled in ONL Therapeutics' Phase 2 GALAXY Trial for Geographic Atrophy #None #Switzerland #Geographic_Atrophy #ONL_Therapeutics #Xelafaslatide

Prevent Blindness Proclaims Annual Geographic Atrophy Week to Enhance Public Awareness Prevent Blindness has announced the fifth annual Geographic Atrophy Week from Dec. 1-7, 2025, aimed at raising awareness about this eye disease affecting millions.

Prevent Blindness Proclaims Annual Geographic Atrophy Week to Enhance Public Awareness #United_States #Chicago #AMD #Geographic_Atrophy #Prevent_Blindness

Astellas and Barbara Costello Partner to Raise Awareness of Geographic Atrophy Astellas Pharma collaborates with Barbara Costello to raise awareness about geographic atrophy and its impact on vision. Discover Babs' personal story and the importance of regular eye exams.

Astellas and Barbara Costello Partner to Raise Awareness of Geographic Atrophy #USA #Astellas_Pharma #Geographic_Atrophy #Babs_Costello #Northbrook,_IL

Recent Findings Highlight Long-Term Benefits of IZERVAY™ in Treating Geographic Atrophy The open-label extension study reveals IZERVAY's effectiveness in reducing geographic atrophy progression and ensuring patient safety over the long term.

Recent Findings Highlight Long-Term Benefits of IZERVAY™ in Treating Geographic Atrophy #Japan #Tokyo #Astellas_Pharma #IZERVAY #Geographic_Atrophy

Astellas to Showcase Promising Findings on IZERVAY™ at AAO 2025 Annual Meeting Astellas Pharma is set to present new insights on IZERVAY™, addressing geographic atrophy at the AAO 2025 Annual Meeting, emphasizing innovation in ophthalmology.

Astellas to Showcase Promising Findings on IZERVAY™ at AAO 2025 Annual Meeting #Japan #Tokyo #Astellas #IZERVAY #Geographic_Atrophy

Astellas to Showcase New Findings on Geographic Atrophy at Vision Congresses Astellas Pharma will present new research on Geographic Atrophy at major ophthalmology conferences, focusing on patient experiences and disease progression.

Astellas to Showcase New Findings on Geographic Atrophy at Vision Congresses #Japan #Tokyo #Astellas #IZERVAY #Geographic_Atrophy

Astellas' IZERVAY™ Receives FDA Approval for Extended Administering Period in Geographic Atrophy Treatment Astellas Pharma's IZERVAY™ gains FDA's nod for indefinite dosing in treating geographic atrophy, enhancing patient flexibility and management options.

Astellas' IZERVAY™ Receives FDA Approval for Extended Administering Period in Geographic Atrophy Treatment #USA #Tokyo #Astellas #Geographic_Atrophy #IZERVAY™

Astellas Pharma Submits New Drug Application for Avacincaptad Pegol in Japan Astellas Pharma has submitted a New Drug Application for avacincaptad pegol, which may be the first treatment for geographic atrophy in Japan. This is a notable step for AMD patients.

Astellas Pharma Submits New Drug Application for Avacincaptad Pegol in Japan #Japan #Tokyo #Astellas #Geographic_Atrophy #Avacincaptad

FDA Approves Resubmission for Astellas Pharma's IZERVAY™ to Treat Geographic Atrophy Astellas Pharma's supplemental New Drug Application for IZERVAY™ has been accepted by the U.S. FDA, aimed at treating geographic atrophy associated with AMD.

FDA Approves Resubmission for Astellas Pharma's IZERVAY™ to Treat Geographic Atrophy #United_States #Tokyo #Astellas_Pharma #IZERVAY #Geographic_Atrophy